Alvotech and Cipla have joined forces to bring biosimilars to treat oncology and autoimmune diseases to South Africa.
Reykjavik, Iceland-based Alvotech has partnered with Cipla Medpro to bring 5 biosimilar candidates to South Africa.
The portfolio will include 2 biosimilar candidates for oncology and 3 for autoimmune diseases; however, the 5 molecules that the biosimilars will reference were not publicly disclosed.
Alvotech will be in charge of development and supply of the products and Cipla will be responsible for commercialization and regulatory registration.
“We’re delighted to establish this important partnership with Cipla…an ideal commercial partner, with a leading presence in the South African pharmaceutical market,” Mark Levick, CEO of Alvotech, said in a statement.
Alvotech’s Other Partners
Alvotech does not have any biosimilars approved yet, but it has been setting other deals for biosimilar distribution with diverse business partners, possibly involving the same biosimilar candidates but in different geographic areas.
In September 2020, Alvotech extended its partnership with DKSH to include distribution of multiple biosimilar products in Asia, the United States, and Europe. Alvotech said this would involve distribution of an adalimumab biosimilar candidate (AVT02).
In August 2020, Alvotech announced a partnership with Teva Pharmaceuticals to commercialize 5 biosimilar candidates for the US market.
Additionally, Avotech has a partnership with JAMP Pharma to market 5 biosimilar candidates in the Canadian market and with Kamada for 6 biosimilar candidates in the Israeli market.
Except for AVT02, Alvotech and its partners have not disclosed any of the molecules included in the deals and there is no information on whether any of the candidates are the same between the deals.
More on Cipla Medpro
Cipla Medpro was founded in South Africa in 1995 under the name Enaleni Pharmaceuticals. Cipla Medpro mostly focuses on over-the-counter and generic medications.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.